Skip to content

Abivax

  • EN
  • FR
  • About Abivax
    • Our Mission
    • Company History
    • Our Leadership
    • Contact Us
  • Our Science
    • Novel MOA
    • Obefazimod
  • Our Research
  • Our Pipeline
  • Publications
  • Investors
    • Overview
    • Press Releases
    • News
    • Share Price
    • Investor Documents
    • General Meeting
    • Corporate Presentation
  • EN
  • FR

News & Events

Press Coverage

  • 2023
  • 2022
  • 2021
  • 2020
  • 2019

IBD News Today

January 4, 2019

Abivax to Present Results of Trials of ABX464 as Ulcerative Colitis Therapy

Labiotech

December 15, 2018

Abivax Spots an Extra Benefit of its Potential HIV Cure

Labiotech

November 6, 2018

Potential HIV Cure Shows Early Stage Promise

Healio

September 6, 2018

Ulcerative colitis drug shows efficacy in European phase 2 trial

Drug Development Technology

September 5, 2018

Abivax reports positive topline results from ABX464-101 trial for UC

  • 1
  • …
  • 36
  • 37
  • 38
  • 39
  • 40
  • …
  • 46

References available upon request.

© 2025 All rights reserved by Abivax 07/2024 Privacy and Terms of Use
Consent Preferences
  • About Abivax
    • Our Mission
    • Company History
    • Our Leadership
    • Contact Us
  • Our Science
    • Novel MOA
    • Obefazimod
  • Our Research
  • Our Pipeline
  • Publications
  • Investors
    • Overview
    • Press Releases
    • News
    • Share Price
    • Investor Documents
    • General Meeting
    • Corporate Presentation
Contact Us
  • Follow us on Twitter
  • Follow us on LinkedIn